Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-tubulin is a highly conserved eukaryotic protein that polymerizes with alpha-tubulin to form microtubules, which are essential components of the cellular cytoskeleton [UniProt: P07437]. These dynamic structures play a fundamental role in cell division by forming the mitotic spindle, which is responsible for the precise segregation of chromosomes into daughter cells [PubMed: 21860390]. Beyond mitosis, microtubules are critical for maintaining cell polarity, facilitating intracellular trafficking of organelles and vesicles, and enabling cell movement through cilia and flagella [NIH: PMC3155166]. In clinical practice, beta-tubulin is a major therapeutic target for anti-cancer drugs, which interfere with microtubule dynamics to induce mitotic arrest and programmed cell death [StatPearls: NBK541084]. However, because microtubules are also vital for the structural integrity and transport mechanisms of neurons, drugs targeting this protein often cause significant side effects, most notably peripheral neuropathy [PubMed: 25236393]. Resistance to tubulin-binding agents is frequently associated with the differential expression of specific beta-tubulin isotypes, such as TUBB3, making it a key area of study for personalized oncology [PubMed: 20570927].
Microtubule-targeting agents (MTAs) act via two primary mechanisms: 1) Microtubule stabilization, where drugs like taxanes and epothilones bind to the beta-tubulin subunit within the microtubule polymer, decreasing the critical concentration of tubulin required for assembly and preventing disassembly; 2) Microtubule destabilization, where drugs like vinca alkaloids and colchicine bind to tubulin dimers to inhibit their polymerization into microtubules. Both mechanisms interfere with the dynamic instability of the mitotic spindle, leading to cell cycle arrest at the G2/M phase and subsequent apoptosis [StatPearls: NBK541084; PubMed: 24507545].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-tubulin (TUBB) (TUBB).